Qing-Xiu Huang1, Jian-Bo Li2,3, Naya Huang2,3, Xiao-Wen Huang4, Yan-Lin Li1, Feng-Xian Huang5,6. 1. Department of Nephrology, Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, China. 2. Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 3. Key Laboratory of Nephrology, National Health Commission and Guangdong Province, Guangzhou, China. 4. Department of Ultrasonography, Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, China. 5. Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, hfxyl@163.net. 6. Key Laboratory of Nephrology, National Health Commission and Guangdong Province, Guangzhou, China, hfxyl@163.net.
Abstract
INTRODUCTION: Studies have shown inconsistent results regarding the association between osteoprotegerin (OPG) concentration and cardiovascular mortality in patients with chronic kidney disease (CKD). This systematic review and meta-analysis aims to investigate the association between OPG concentration and cardiovascular mortality in patients with CKD. METHODS: Between January 1970 and February 2020, the PubMed, EMBASE, and Cochrane Library databases were searched for eligible studies investigating the association between OPG concentration and cardiovascular mortality in patients with CKD. Pooled hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were calculated using random effects models. RESULTS: In total, 10 studies comprising 2,120 patients (including 1,723 receiving dialysis) with CKD were included. The included studies were considered to be of fair to high quality. Patients in the highest OPG concentration group had a significantly higher risk of cardiovascular mortality (4 studies; adjusted HR, 2.05; 95% CI, 1.39-3.00) than patients in the low OPG concentration group. An increase of 1 pmol/L in OPG concentration was associated with a 4% increased risk of cardiovascular mortality (6 studies; adjusted HR, 1.04; 95% CI, 1.02-1.07). CONCLUSION: Elevated OPG concentrations are associated with an increased risk of cardiovascular death in patients with CKD.
INTRODUCTION: Studies have shown inconsistent results regarding the association between osteoprotegerin (OPG) concentration and cardiovascular mortality in patients with chronic kidney disease (CKD). This systematic review and meta-analysis aims to investigate the association between OPG concentration and cardiovascular mortality in patients with CKD. METHODS: Between January 1970 and February 2020, the PubMed, EMBASE, and Cochrane Library databases were searched for eligible studies investigating the association between OPG concentration and cardiovascular mortality in patients with CKD. Pooled hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were calculated using random effects models. RESULTS: In total, 10 studies comprising 2,120 patients (including 1,723 receiving dialysis) with CKD were included. The included studies were considered to be of fair to high quality. Patients in the highest OPG concentration group had a significantly higher risk of cardiovascular mortality (4 studies; adjusted HR, 2.05; 95% CI, 1.39-3.00) than patients in the low OPG concentration group. An increase of 1 pmol/L in OPG concentration was associated with a 4% increased risk of cardiovascular mortality (6 studies; adjusted HR, 1.04; 95% CI, 1.02-1.07). CONCLUSION: Elevated OPG concentrations are associated with an increased risk of cardiovascular death in patients with CKD.
Authors: Marcela Ávila; Ma Del Carmen Prado; Renata Romero; Ricardo Córdova; Ma Del Carmen Rigo; Miguel Trejo; Carmen Mora; Ramón Paniagua Journal: Biomolecules Date: 2022-04-08
Authors: Sang Heon Suh; Tae Ryom Oh; Hong Sang Choi; Chang Seong Kim; Kook-Hwan Oh; Joongyub Lee; Yun Kyu Oh; Ji Yong Jung; Kyu Hun Choi; Seong Kwon Ma; Eun Hui Bae; Soo Wan Kim Journal: J Clin Med Date: 2021-12-29 Impact factor: 4.241
Authors: Joanna Kamińska; Marek Stopiński; Krzysztof Mucha; Michał Pac; Marek Gołębiowski; Monika A Niewczas; Leszek Pączek; Bartosz Foroncewicz Journal: Int J Gen Med Date: 2021-06-09